Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer (Q38002896)

26 August 2017

Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer (English)

1 reference

26 August 2017

0 references

1 reference

Carlo Genova

1

1 reference

ORCID Public Data File 2021

author name string

Erika Rijavec

2

1 reference

26 August 2017

Giulia Barletta

3

1 reference

26 August 2017

Claudio Sini

4

1 reference

26 August 2017

Maria Giovanna Dal Bello

5

1 reference

26 August 2017

Mauro Truini

6

1 reference

26 August 2017

Carmelina Murolo

7

1 reference

26 August 2017

Paolo Pronzato

8

1 reference

26 August 2017

Francesco Grossi

9

1 reference

26 August 2017

language of work or name

English

0 references

publication date

16 April 2012

1 reference

Expert Opinion on Biological Therapy

26 August 2017

1 reference

26 August 2017

12

1 reference

26 August 2017

7

1 reference

26 August 2017

939-948

1 reference

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Manipulation of costimulatory signals to enhance antitumor T-cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Regulatory T cells in immune surveillance and treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

CTLA-4 can function as a negative regulator of T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Ipilimumab: controversies in its development, utility and autoimmune adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Anti-CTL-associated antigen 4: are regulatory T cells a target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.681371

Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2006.24.18_SUPPL.4609

Identifiers

DOI

10.1517/14712598.2012.681371

1 reference

26 August 2017

1 reference